(Sharecast News) - British drugs giant GSK has agreed to buy Rapt Therapeutics in a $2.2bn deal, it was announced on Tuesday, sending shares in the American allergy specialist soaring.
Under the terms of the deal, GSK will pay Rapt shareholders $58 per share, giving the California-based firm an estimated aggregate...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE